Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 1012345...10...Last »

From gene editing to death traps, Seattle scientists innovate in race to end malaria

The world has made huge strides against malaria since 2000, with death rates plunging by 60 percent and at least six million lives saved globally, says the World Health Organization (WHO). Yet efforts to end one of the world’s deadliest diseases – which killed an estimated 438,000 people in 2015 – are under threat as mosquitoes become increasingly resistant to measures such as insecticide-treated bednets and anti-malarial drugs.

Read More »

Industry funded studies do not find sweet drinks linked to obesity, diabetes

Do sugar-sweetened beverages like soda and fruit drinks cause obesity and diabetes? The answer may depend on who funds the research asking the question.

Read More »

Using, and even just thinking about portable media may disrupt kids’ sleep

Children and teens with access to tablets and smartphones at night do not get enough sleep and are sleepier during the day, whether or not they use the devices, according to a new review.

Read More »

Celgene Eyes $6 Billion in New Business

Only a month ago, Sean Williams of The Motley Fool noted that Celgene was a company whose stocks were running a little low, but was likely to explode. There are many reasons, but today Stephen Simpson, also writing for The Motley Fool, outlines how the company’s immunology and inflammation (I&I) efforts could bring in $6 billion in new revenue.

Read More »

Mylan’s Meda AB to Shutter U.S. HQ, 94 Jobs Gone

Two months after completing its $7.2 billion acquisition of Meda, Mylan is terminating 94 employees and shuttering the Swedish company’s N.J. headquarters.

Read More »

FDA Spurns RA Drug Over Plant Deficiencies

A Complete Response Letter was issued by the U.S. FDA regarding the BLA for sarilumab, a rheumatoid arthritis drug being co-developed by Regeneron and Sanofi.

Read More »

Third Rock Ventures Raises $616 Million Fund IV

Third Rock Ventures LLC announced the closing of Third Rock Ventures IV LP (“Fund IV”), raising $616 million in an oversubscribed fund. With Fund IV, the firm will continue to execute on its strategy of creating innovative healthcare companies to make a meaningful difference in the lives of patients and their families.

Read More »

An essay on snark, literary critique, and hipster douchebags

(Reprinted coming from the Chicago Facility for Literature and Photography. I am just an original writer on this essay, along with the proprietor of CCLaP; it is not necessarily currently being reprinted here unlawfully.) Typical site visitors I’m sure chances are have captured to how I really like to glance at the creating routine here […]

Read More »

One in seven children suffer high air pollution: UNICEF

Almost one in seven children worldwide live in areas with high levels of outdoor air pollution, mostly in South Asia, and their growing bodies are most vulnerable to damage, the U.N. children’s agency UNICEF said.

Read More »

St. Jude halts one of its pacemaker implants

Medical device maker St. Jude Medical Inc. said it has notified doctors to stop implants of one of its cardiac pacemakers, citing reports of problems with electronic data reporting caused by a battery malfunction that could put patients at risk.

Read More »

First U.S. soda tax cuts consumption beyond expectations

As voters consider soda taxes in four U.S. cities, a new study finds that low-income Berkeley neighborhoods slashed sugar-sweetened beverage consumption by more than one-fifth after the Northern California city enacted the nation’s first soda tax.

Read More »

Amazon CEO, Mayo Clinic Back Bay Area Anti-Aging Firm Unity Biotech’s $116 Million Funding Round

Antiaging startup Unity Biotechnology got an infusion of $116 million in financing – backed in part by noted names, including Jeff Bezos, the founder of – through his Bezos Expedition Fund, as well as ARCH Venture Partners and Mayo Clinic Ventures.

Read More »

Ganymed Grabs $1.4 Billion Buyout From Astellas

Astellas Pharma plunked down $1.4 billion to acquire Ganymed Pharmaceuticals and its experimental pipeline asset IMAB362 as a first-line treatment in gastric cancer.

Read More »

Exclusive: EpiPen price hikes add millions to Pentagon costs

Mylan NV’s price hikes on EpiPens have added millions to U.S. Department of Defense spending since 2008 as the agency covered more prescriptions for the lifesaving allergy shot at near retail prices, government data provided to Reuters shows.

Read More »

Screen time, phone use linked to less sleep for teens

Digital distractions, and a more classical one – talking on the phone – are linked to shorter sleeping time and greater daytime sleepiness for teens, Canadian researchers say.

Read More »

Could nasal tissue repair a damaged knee joint?

Doctors might one day be able to harvest cells from patients’ noses to produce cartilage that can be transplanted into damaged knee joints.

Read More »

AstraZeneca pauses two cancer drug trials’ enrollment due to bleeding

AstraZeneca’s high hopes for cancer immunotherapy were dented as the recruitment of new patients with head and neck cancer into two clinical studies was put on hold, following instances of bleeding.

Read More »

Patient values may not always align with choices for end of life care

Patients and families state that they value comfort, having time with family and death not being prolonged, but these values often do not align with the treatment they expect at the end of life, according to a new Canadian study.

Read More »

Allergan Acquires Gastrintestinal Firm Motus

Allergan struck a $200 million deal to snag Motus Therapeutics in an effort to shore up its gastrointestinal therapies.

Read More »

Bristol-Myers Squibb to Revamp R&D Unit

Following an unexpected clinical-trial setback of Bristol-Myers Squibb’s Opdivo, the company plans to undergo a reorganization of its research and development unit.

Read More »

Page 1 of 1012345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom